Replies to post #11824 on GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

>looking over the entire history of GTCB as some kind of predictor of what will happen in the near future. That is clearly wrong<
Up and down sir: the goat process is NON-ERGODIC.

[DragonBits]

The EMEA barely approved ATryn, and then only after Genzyme intervened. I don't know if there have been any sales of ATryn, has there? Because at least if there has been sales that is some form of data that will reassure the FDA.

Because FDA approval is hardly assured, we have seen many times FDA reject something that the EMEA has approved.

Clearly past performace does predict future performance, and it is a pretty reliable predictor. What you are hoping for is that this time it will be different. But the mircocap biotech world is littered with investors that hoped it would be different this time.

I believe whatever the next deal GTC stikes, be it private placement or partnership, should tell us a lot about if anything has changed. I can wait to see what that deal is, or wait to buy if GTC tanks 50%. Either or.